Insulet Corporation Earnings Recaps
Insulet shares rose 6.6% after the company reported third-quarter revenue growth of nearly 20% and narrowed its full-year 2026 revenue outlook to the top end of its prior range. The positive reaction comes alongside a note of caution: management expects to take a more conservative approach to its 2027 outlook as competition increases.
Key takeaways
- Revenue was $842 million, up nearly 20% year over year: approximately 15% growth in the U.S. and 33% internationally.
- The global customer base grew more than 20%; new customer starts were up low single digits in Q3, though year-to-date starts grew low double digits.
- Type 2 patients accounted for over 40% of U.S. starts; more than 85% of Omnipod starts came from people switching from multiple daily injections.
- Management cited record gross margin and expanded operating margin, but gave no margin figures in the excerpt.
- The board approved an additional $1 billion in share repurchase authorization; Insulet expects to repurchase $400 million in Q4 using cash on hand.
Shares fell sharply by 16.5% as investors reacted negatively to the unexpected deceleration in type 2 diabetes customer retention and the need for increased investment in customer support, signaling concerns about the sustainability of growth in this key segment.
Key takeaways
- Total company revenue grew 23% year-over-year on a constant currency basis, driven by strong demand and favorable price mix.
- Adjusted operating margin improved by 140 basis points, reflecting better manufacturing productivity and scale benefits.
- Adjusted EPS increased approximately 42%, supported by revenue growth and cost discipline.
- New global customer starts reached the second highest quarter ever, with strong U.S. MDI user conversions and international expansion in Spain.
- Retention and utilization among type 2 diabetes customers weakened more than anticipated, prompting a strategic shift to expand customer care, modify sales incentives, and refine sampling programs to address lower engagement and retention risks.
Shares declined 4.3% after Insulet’s earnings call as investors reacted negatively to a cautious outlook shaped by seasonal headwinds in the U.S. diabetes market and modest deceleration in early-year revenue trends, despite raised full-year guidance.
Key takeaways
- Reported 30% revenue growth in Q1 2026, including 28% growth in the U.S. and 45% internationally.
- Adjusted operating margin expanded by 110 basis points year-over-year, driving roughly 40% adjusted EPS growth.
- Management cited unusual seasonality effects from annual insurance deductible resets, causing a slower start in U.S. market demand.
- Though full-year revenue growth guidance was slightly raised to 21–23%, early quarter softness and cautious tone on U.S. trends weighed on sentiment.
- Continued progress internationally with strong new customer starts and expanded reimbursement coverage, particularly in Canada and Europe.
Insulet Corporation delivered a remarkable third quarter in 2025, achieving over $700 million in revenue, reflecting a 28% year-over-year growth, driven by strong customer retention and expansion in both Type 1 and Type 2 markets.
Key takeaways
- Surpassed $700 million in quarterly revenue for the first time, demonstrating the strength of its recurring revenue model.
- Operating margins increased by 90 basis points to 17.1%, reflecting efficient cost management alongside investments in innovation.
- New customer starts in the U.S. Type 2 market more than doubled year-over-year, highlighting strong momentum and effective outreach strategies.
- International revenue grew 40% year-over-year, driven by successful global launches, including Omnipod 5, and strong demand in established markets.
- The expanded leadership team aims to further enhance Insulet's market position and customer experience across various segments.